Capillary-selective vasodilation through myosin inhibition halts ischaemic cascades

AI Insight

Researchers have identified a compound called R(+)2501 that selectively dilates capillaries by inhibiting myosin in pericytes, the cells that wrap around capillaries and control blood flow. When tested in animal models of myocardial infarction and acute kidney injury, this compound reversed capillary no-reflow—a condition where blood fails to reach tissues despite open arteries—by relaxing pericytes and restoring microvascular perfusion. The treatment improved survival rates in the animal models studied.

Why it matters

This finding addresses a critical gap in treating ischemic injuries, where restoring blood flow to large vessels does not always prevent tissue damage due to persistent blockages at the capillary level. The compound could potentially be developed into a therapeutic intervention for heart attacks, acute kidney injury, and other conditions where microvascular dysfunction contributes to organ damage.